Home Aminos 2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid hydrochloride

2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid hydrochloride

CAS No.:
405911-17-3
Catalog Number:
AG003QTS
Molecular Formula:
C33H32Cl2F3NO3
Molecular Weight:
618.5133
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$105
- +
5mg
99%
1 week
United States
$157
- +
10mg
99%
1 week
United States
$223
- +
50mg
99%
1 week
United States
$707
- +
100mg
99%
1 week
United States
$1173
- +
Product Description
Catalog Number:
AG003QTS
Chemical Name:
2-[3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid hydrochloride
CAS Number:
405911-17-3
Molecular Formula:
C33H32Cl2F3NO3
Molecular Weight:
618.5133
MDL Number:
MFCD08276920
IUPAC Name:
2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid;hydrochloride
InChI:
InChI=1S/C33H31ClF3NO3.ClH/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26;/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40);1H
InChI Key:
NMPUWJFHNOUNQU-UHFFFAOYSA-N
SMILES:
OC(=O)Cc1cccc(c1)OCCCN(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F.Cl
Properties
Complexity:
753  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
617.171g/mol
Formal Charge:
0
Heavy Atom Count:
42  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
618.518g/mol
Monoisotopic Mass:
617.171g/mol
Rotatable Bond Count:
13  
Topological Polar Surface Area:
49.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
B-13 progenitor-derived hepatocytes (B-13/H cells) model lipid dysregulation in response to drugs and chemicals. Toxicology 20170701
Cadmium-induced malignant transformation of rat liver cells: Potential key role and regulatory mechanism of altered apolipoprotein E expression in enhanced invasiveness. Toxicology 20170501
Liver X receptor activation promotes differentiation of regulatory T cells. PloS one 20170101
Influence of liver-X-receptor on tissue cholesterol, coenzyme Q and dolichol content. Molecular membrane biology 20121101
Regulation of sphingomyelin phosphodiesterase acid-like 3A gene (SMPDL3A) by liver X receptors. Molecular pharmacology 20121001
Liver X receptors agonists impede hepatitis C virus infection in an Idol-dependent manner. Antiviral research 20120901
Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2. Arteriosclerosis, thrombosis, and vascular biology 20120901
Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expression of fatty acid desaturases 1 and 2 and modulate response to simvastatin. Prostaglandins, leukotrienes, and essential fatty acids 20120701
ABCA1 upregulating apolipoproein M expression mediates via the RXR/LXR pathway in HepG2 cells. Biochemical and biophysical research communications 20120427
Liver X receptor activation enhances blood-brain barrier integrity in the ischemic brain and increases the abundance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells. Brain pathology (Zurich, Switzerland) 20120301
Liver X receptor activation downregulates organic anion transporter 1 (OAT1) in the renal proximal tubule. American journal of physiology. Renal physiology 20120301
Liver x receptors regulate the transcriptional activity of the glucocorticoid receptor: implications for the carbohydrate metabolism. PloS one 20120101
Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model. The Journal of neuroscience : the official journal of the Society for Neuroscience 20111102
Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism. The Journal of biological chemistry 20110923
Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα. The American journal of pathology 20110701
LXR as a novel antithrombotic target. Blood 20110526
Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4. Journal of immunology (Baltimore, Md. : 1950) 20110415
Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. British journal of pharmacology 20110401
Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity. Journal of lipid research 20101201
ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. The Journal of biological chemistry 20101029
Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy. The Journal of neuroscience : the official journal of the Society for Neuroscience 20100908
Recent progress in liver X receptor-selective modulators. Current opinion in drug discovery & development 20100701
The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. The Journal of biological chemistry 20100625
X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling. Journal of molecular biology 20100528
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. Journal of lipid research 20100401
The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation. Journal of cellular physiology 20100401
Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arteriosclerosis, thrombosis, and vascular biology 20100401
Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling. The Journal of biological chemistry 20100219
Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages. Shock (Augusta, Ga.) 20091101
LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis 20091101
Activation of liver X receptor regulates substrate oxidation in white adipocytes. Endocrinology 20090901
The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro. Diabetologia 20090701
Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell metabolism 20081201
Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. Journal of immunology (Baltimore, Md. : 1950) 20081115
Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS letters 20081015
Intestine-specific regulation of PPARalpha gene transcription by liver X receptors. Endocrinology 20081001
Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 20080930
Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. Journal of immunology (Baltimore, Md. : 1950) 20080915
Androgen deprivation by activating the liver X receptor. Endocrinology 20080801
PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine. Biochemical and biophysical research communications 20080711
Ligand specificity and evolution of liver X receptors. The Journal of steroid biochemistry and molecular biology 20080501
Combination of virtual screening and high throughput gene profiling for identification of novel liver X receptor modulators. Journal of medicinal chemistry 20080410
Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arteriosclerosis, thrombosis, and vascular biology 20080301
The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 20080101
Liver X receptors (LXR) as therapeutic targets in dyslipidemia. Cardiovascular therapeutics 20080101
Physiological differences between human and rat primary hepatocytes in response to liver X receptor activation by 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyloxy]phenylacetic acid hydrochloride (GW3965). Molecular pharmacology 20071001
GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. British journal of pharmacology 20070601
Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists. Molecular human reproduction 20070601
[Advances in the study of anti-atherosclerosis drugs]. Yao xue xue bao = Acta pharmaceutica Sinica 20070301
Chlamydia pneumoniae--induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infection and immunity 20070201
The nuclear receptor LXR is a glucose sensor. Nature 20070111
Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circulation research 20060929
Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study. Journal of lipid research 20060601
A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. The Journal of biological chemistry 20060224
Oxysterols suppress inducible nitric oxide synthase expression in lipopolysaccharide-stimulated astrocytes through liver X receptor. Neuroreport 20060206
Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation. Shock (Augusta, Ga.) 20060201
Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 20060103
Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. American journal of physiology. Endocrinology and metabolism 20051101
Synthetic LXR agonists increase LDL in CETP species. Journal of lipid research 20051001
Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circulation research 20041210
Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. Journal of lipid research 20040801
Miniaturization of cell-based beta-lactamase-dependent FRET assays to ultra-high throughput formats to identify agonists of human liver X receptors. Assay and drug development technologies 20031201
FXRE can function as an LXRE in the promoter of human ileal bile acid-binding protein (I-BABP) gene. FEBS letters 20031023
Properties